Trials / Completed
CompletedNCT00802373
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,355 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solifenacin succinate | oral |
| DRUG | Tolterodine | Oral |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2004-10-01
- Completion
- 2004-10-01
- First posted
- 2008-12-04
- Last updated
- 2014-09-18
Locations
95 sites across 17 countries: Belarus, Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Russia, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00802373. Inclusion in this directory is not an endorsement.